IUS during [2003] [2004] were identified in the MarketScan claims database (2002) (2003) (2004) (2005) . Only women with two years of continuous eligibility around the devise insertion date (1-year before and 1-year after insertion) were included. Clinical outcomes included were menorrhagia or irregular bleeding, dysmenorrhea, and fibroids-related symptoms. Economic outcomes included the number of emergency room visits, number of office visits, and health care costs. Both economic and clinical outcomes were measured and compared between the one year pre-insertion and one year post-insertion. McNemar's test was used to test for significant changes in dichotomous variables and the paired t test was used for continuous variables. RESULTS: Three thousand nine hundred seventy-nine women received LNG-IUS. Mean age was 33.6 years (S.D. = 6.7 years).
During one year after the LNG-IUS insertion, women experienced significantly less dysmenorrhea (1.5% vs. 2.0%, relative risk [RR] = 0.74, p = 0.014) and less fibroids-related symptoms (2.1% vs. 2.4%, RR = 0.86, p = 0.046). No significant differences were found in menorrhagia or irregular bleeding. Emergency room visits also were significantly reduced (RR = 0.90, p < 0.001). Outpatient office visits dropped from 12.5 visits during the pre-insertion year to 10.4 visits during the postinsertion year (p < 0.001). The total direct health care costs were $5565 during the year before LNG-IUS use vs. $3141 during the year after, resulting in a $2424 reduction (p < 0.001). The majority of the cost savings were due to the cost reduction associated with inpatient hospitalizations. CONCLUSION: During the first year after LNG-IUS insertion, women experienced significant less dysmenorrhea and fibroids-related symptoms. The use of LNG-IUS was also associated with reduction in resource utilization and health care costs.
WH4 PROBIOTICS IN PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES
Dugoua JJ 1 , Zhu X 1 , Chen X 1 , Koren G 2 , Machado M 1 , Einarson TR 1 1 University of Toronto, Toronto, ON, Canada, 2 Hospital for Sick Children, Toronto, ON, Canada OBJECTIVE: Probiotics are live bacteria or non-pathogenic yeasts that colonize the gastrointestinal tract, providing health benefits to the host. Their safety has not been systematically investigated in pregnancy. Our objective was to review the evidence for safety of Lactobacillus, Bifidobacterium, and Saccharomyces during pregnancy. METHODS: Accepted were randomized controlled trials comparing probiotics and placebo given any time during pregnancy, at any dose, in any form, for any condition, and given Ն1 week. Outcomes included birth weight, gestational age (GA), rates of C-section, malformations (major/minor), and miscarriage. Two independent reviewers searched databases (MEDLINE, OLDMEDLINE, CINAHL, Cochrane Database, DARE, Allied and Complementary Medicine, EMBASE, AltHealthWatch, American Botanical Council, Natural Database, and Natural Standard) from inception to September 2007, hand-searched their bibliographies, and contacted experts to identify other trials. Two reviewers extracted data and assessed study quality using the Downs-Black checklist. Discrepancies (study eligibility, data, quality) were adjudicated through consensus. Heterogeneity was assessed with chi-squared and I-squared tests, publication bias with Begg-Mazumdar test. Random-effects models combined data. RESULTS: Nine studies examined 1706 patients for three outcomes; none examined birth defects or miscarriages. Publication bias was not detected Abstracts A27
